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Abstract
Background: The participation of immune/inflammatory mechanisms in the pathogenesis of tropical endomyocardial
fibrosis (EMF) has been suggested by the finding of early blood and myocardial eosinophilia. However, the inflammatory
activation status of late-stage EMF patients is still unknown.
Methodology/Principal findings: We evaluated pro- and anti-inflammatory cytokine levels in plasma samples from late
stage EMF patients. Cytokine levels of Tumor Necrosis Factor (TNF)-a, Interferon (IFN)-c, Interleukin (IL)-2, IL-4, IL-6, and IL-10
were assayed in plasma samples from 27 EMF patients and compared with those of healthy control subjects. All EMF
patients displayed detectable plasma levels of at least one of the cytokines tested. We found that TNF-a, IL-6, IL-4, and IL-10
were each detected in at least 74% of tested sera, and plasma levels of IL-10, IL-4, and TNF-a were significantly higher than
those of controls. Plasma levels of such cytokines positively correlated with each other.
Conclusions/Significance: The mixed pro- and anti-inflammatory/Th2circulating cytokine profile in EMF is consistent with
the presence of a persistent inflammatory stimulus. On the other hand, the detection of increased levels of TNF-a may be
secondary to the cardiovascular involvement observed in these patients, whereas IL-4 and IL-10 may have been upregulated
as a homeostatic mechanism to buffer both production and deleterious cardiovascular effects of pro-inflammatory
cytokines. Further studies might establish whether these findings play a role in disease pathogenesis.
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Introduction
Tropical endomyocardial fibrosis (EMF) is a restrictive cardio-
myopathy characterized by fibrous tissue deposition of the
endomyocardium of one or both ventricles, associated with
diastolic heart failure (HF), secondary valvular dysfunction, and
atrial arrhythmias, such as atrial fibrillation (AF). The etiopatho-
genesis of EMF is still obscure [1]. Several factors involving
immune mechanisms have been suggested to play a pathogenetic
role, including infections, chronic helminthic infection-related
hypereosinophilia, allergy, auto-immunity, and malnutrition. One
of the major pathogenetic theories states that EMF could be
considered a late effect of helminthic infection-induced eosinophil
degranulation in the heart,due to its similarities with the
eosinophilic endocarditis (EE) of Loeffler’s syndrome [2–4]. At
the late stage of the disease, the presence of a focal perivascular
chronic inflammatory infiltrate deep within the endomyocardium,
predominantly composed by lymphocytes and macrophages, with
very rare eosinophils is consistent with a role of persistent immune-
mediated inflammation [5]. Cytokines are key mediators of
immunity, modulating the nature of the immune and inflamma-
tory responses. Proinflammatory cytokines such as TNF-a and IL-
6 have been found to be increased both in peripheral blood and
heart tissue, in several cardiovascular (CV) diseases including HF
[6–8] and have prognostic significance [9,10].
Direct pathogenic effects of TNF-a include progressive cardio-
myocyte apoptosis, adverse ventricular remodelling, left ventric-
ular (LV) wall thinning and dilation, which have been observed in
mice overexpressing TNF-a [11]. Anti-inflammatory cytokines
such as IL-4 and IL-10 are associated with helminthiasis and
eosinophilia [12] and a limited number of studies have reported
the detection ofsuch cytokines in CV disorders [13,14]. Several of
the clinical features characteristic of EMF are associated them-
selves with increased levels of circulating cytokines [15]. Even
though a persistent local inflammatory infiltrate is found in
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late-stage EMF, it is yet unknown whether such patients display
systemic inflammatory activation.In order to assess whether there
is systemic inflammation in the late stages of EMF, we assessed the
circulating levels of pro- and anti-inflammatory/Th2 cytokines in
EMF patients and controls.
Methods
The protocol was approved by the Institutional Review Board
of the University of Sa˜o Paulo School of Medicine (Protocol
number 0569/10), and written informed consent was obtained
from all the subjects.
Patient selection
We evaluated cytokine plasma levels of 27 EMF outpatients (24
female, 34.6615.5 years) followed at the Cardiomyopathy Unit of
the Heart Institute (InCor), University of Sa˜o Paulo Medical
School between 2004 and 2012, and 38 healthy blood donors (26
female, 33.9612.0 years) from Pro´-Sangue Foundation, as control
subjects. Patients had undergone bidimensional Doppler echocar-
diography and gadolinium-enhanced magnetic resonance imag-
ing. The major inclusion criteria included clinical signs suggestive
of diastolic HF, apical obliteration of one or both ventricles [16,17]
and late gadolinium enhancement magnetic resonance imaging
showing the typical pattern of fibrous tissue deposition [18]. There
were no exclusion criteria.Nine (30%) patients hadbiventricular,
seven (26%) right ventricular, and eleven (44%) left ventricular
(LV) involvement. Patients came from lower socioeconomic strata,
with poor housing and evidence of protein malnutrition during
childhood. Twenty-one patients (78%) underwent surgical resec-
tion of endomyocardial fibrous tissue; gross anatomy and
histopathology confirmed the diagnosis.
Sample collection and cytokine quantification
EDTA-anticoagulated peripheral blood samples were collected
from the patients and from healthy controls. Plasma samples were
stored at 280uC until cytokine assays were performed, using the
Th1/Th2 II human bead array (BD Biosciences), according to the
manufacturer’s recommendations. Samples were analyzed with
Figure 1. Cytokine plasma levels of endomyocardial fibrosis patients and healthy subjects. Dot plot represents cytokine levels
(interleukin 2, 4, 6, 10, TNF-a and IFN-c) from endomyocardial fibrosis patients (EMF) and healthy subjects (HS), evaluated by CBA. Horizontal lines
indicate the median values. *Differences where P#0.05 are indicated. (NHealthy Subjects;&EMF patients).
doi:10.1371/journal.pone.0108984.g001
Table 1. Demographic and echocardiographic data from EMF patients and healthy subjects.
Variable EMF HS
Gender (Male/Female) 3/24 12/26
Age (years - Male/Female) 34.6615.5 33.9612
Bilateral/RV/LV EMF (%) 49.5613.3 53.9612,9
Mitral regurgitation (%) * 30/26/44 NA
Tricuspid regurgitation (%)* 55.5%/26%/7.4% NA
Diastolic dysfunction grade (%)** 37%/18.5%/7.4% NA
Systolic dysfunction (%) 60,90% NA
AF (%) 21.4 NA
NA – Not applicable; AF – Atrial Fibrillation; (Percentage of EMF patients with the conditionregistered in the medical records); Systolic dysfunction: Ejection Fraction ,
55%; *Valvar regurgitation level: mild, moderate, and severe, respectively; Diastolic dysfunction: grades mild, moderate, and severe ** It was not possible to evaluate
diastolic function in 4 patients, due to the presence of pacemaker or bioprosthetic heart valve.
doi:10.1371/journal.pone.0108984.t001
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the FACSCanto flow cytometer (BD Biosciences), and the FCAP
Array software (BD Biosciences) was used for data analysis.
Statistical Methods
Cytokine levels were compared among EMF patients and
subject controls by using the Mann-Whitney U test. Correlations
of data were analyzed by the non-parametric Spearman test. All
analysis was performed with Graph Pad Prism version 5 software
(GraphPad Software, La Jolla, California, USA). A P value,0.05
was considered statistically significant.
Results
EMF and healthy subjects were age and sexmatched (Table 1).
Plasma samples from all 27 EMF patients examined in this study
showed detectable levels of at least one of the assayed cytokines.
Increased levels of interleukin (IL)-4 (4.5167.79 pg/mL), IL-10
(4.1165.27 pg/mL), and tumor necrosis factor alpha (TNF-a)
(2.7764.64 pg/mL) were detected in a high proportion of EMF
patients (88.8%, 92.6%, and 77.7%, respectively) compared with
healthy control samples (1.2260.87 pg/mL - P= 0.001, 0.996
0.89 pg/mL- P= 0.0001 and 0.9460.24 pg/mL - P= 0.006, res-
pectively - Mann Whitney U Test) - (Figure 1 and 2). There was
no significant difference in IL-6, IFN- c and IL-2 levels compared
with control samples. Interestingly, circulating IL-4 was present in
20/21 samples in which IL-10 was detectable. In addition, a
positive correlation was observed between all cytokine levels in
EMF patients, with the exception of TNF-a and IFN- c (P= 0.08;
Figure 2).
Discussion
Our study shows that EMF patient shave elevated plasma levels
of pro- and anti-inflammatory cytokines, especially TNF-a, IL-4,
and IL-10, which were significantly higher than those in healthy
subjects. The correlation between levels of pro- and anti-
inflammatory/Th2 cytokines may suggest that either the stimuli
that induce both kinds of cytokines are the same, or that IL-10 and
IL-4 may have a regulatory role and control the levels and
deleterious effects of proinflammatory cytokines.
Multiple cardiovascular disorders are associated with increased
levels of circulating pro-inflammatory cytokines, especially TNF-a
and IL-6, which are related to a common cytokine profile found in
acute and chronic HF patients independently of etiology [19,20].
Mann proposed that acute increased levels of IL-6, TNF-a and IL-
1 could be an adaptive response for cardiac injury, with
cardioprotective effects, whereas the chronic elevation of these
mediators could be a maladaptive response and promote cardiac
decompensation [21]. However, the underlying cause for the
presence of the inflammatory response in different CV diseases is
still under investigation [22]. It has been suggested that the
predominant mechanism of upregulation of TNF-a production is
secondary to advanced heart failure itself, such as low cardiac
output and intestinal bacterial translocation [23].
In addition, a limited number of reports on HF have found
increased plasma levels of the other cytokines detected in our study
(IL-10, IL-4, and to a lesser extent IFN- c and IL-2) [13,24–26]. It
is thus possible that the triggers of cytokine production in EMF are
similar to those found in HF with other causes, such as
Figure 2. Correlation among cytokine plasma levels of endomyocardial fibrosis patients. Dot plots represent correlation between
cytokine levels (interleukin 2, 4, 6, 10, TNF-a and IFN-c) from endomyocardial fibrosis patients, evaluated by CBA.
doi:10.1371/journal.pone.0108984.g002
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hypertensive or idiopathic dilated cardiomyopathy. On the other
hand, our findings that late-stage EMF patients display increased
IL-4 and IL-10 levels are also consistent with the observed early
eosinophilia and helminthic infections in EMF, once this type of
infection is usually associated with increased levels of these
cytokines [27–30]. Whichever the stimulus for cytokine production
may be, results suggest a possible relevance of a persisting Th2 (IL-
4 and IL-10) cytokine-driven immune mechanism in the patho-
genesis of EMF. Significantly, IL-10 is an anti-inflammatory
cytokine that may reduce TNF-a production, which may be
clinically significant in the pathogenesis of HF [31]. In our study,
the almost universal co-detection of inflammatory and anti-
inflammatory cytokines, as well as the correlation between their
levels is consistent with such an antagonistic effect. On the other
hand, along with its known anti-inflammatory effects, long-term
overexpression of IL-10 has been associated with lung fibrosis [32].
Although blood eosinophilia (BE) has been reported in EMF
cases [29], less than 40% of our patients displayed BE ($
500 eosinophils/mm3) during follow-up in the chronic phase of
this disease. Our data are consistent with those reported by Patel
and associates (1977) [33], who observed that the absolute BE in
African EMF patients was similar to that of healthy control
subjects. In a recent study from a similar cohort of patients in our
Hospital, Iglezias et al. [5] found no eosinophils in the heart lesions
of EMF patients. Together, these results suggest that neither blood
nor endocardial eosinophilia are essential components of late-stage
EMF. Our data are consistent with the hypothesis that early
helminthic infestation could cause a waning eosinophilia that
might be involved in initial heart damage in EMF pathogenesis,
and along with a long-lasting Th2 response whose pathogenic or
protective potential is yet unclear. However, we cannot exclude
that the anti-inflamatory cytokine levels are raised as a homeo-
static mechanism to buffer both production and effects of pro-
inflammatory cytokines. Although persistent IL-10 production
may lead to lung fibrosis [33], it is unknown whether the cytokine
could accelerate fibrous tissue deposition in the endomyocardium
of EMF patients. One limitation of this study is the lack of
information about helminthic infection status in our patient group.
In summary, we have shown for the first time that late-stage
EMF patients display detectable plasma levels of a mixed pro- and
anti-inflammatory/Th2 cytokine profile, predominantly composed
of TNF-a, IL-10 and IL-4 levels. The finding of such a mixed
cytokine profile may either reflect the multiple cardiovascular
disorders also experienced by EMF patients, or indicate a common
persistent stimulus for production of both pro- and anti-
inflammatory/Th2 cytokines. On the other hand, anti-inflamma-
tory/Th2 cytokines IL-4 and IL-10 may either be upregulated by
previous helminthic infection, or as a homeostatic mechanism to
buffer both production and effects of pro-inflammatory cytokines.
This antagonism is consistent with the almost universal co-
detection of inflammatory and anti-inflammatory cytokines in
EMF plasma samples, as well as the positive correlation between
their plasma levels. Further studies may allow the identification of
the stimulus for chronic cytokine production, and to establish
whether cytokines play a role in pathogenesis or have a prognostic
value for rates of disease progression or post-surgical follow-up.
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